Multiple sclerosis: An immune or neurodegenerative disorder?

Annual Review of Neuroscience

Volumn 31, Issue , 2008, Pages 247-269

  Trapp, Bruce D ^a   Nave, Klaus Armin ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Axon glial interactions; Axonal degeneration; Brain atrophy; Cortical pathology; Demyelination; Myelin

Indexed keywords

BETA INTERFERON; GLATIRAMER; NATALIZUMAB;

DEMYELINATION; DISEASE COURSE; GENETICS; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVE FIBER; NERVE FIBER DEGENERATION; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; AXONS; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; ENCEPHALITIS; HUMANS; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEURODEGENERATIVE DISEASES; NEUROGLIA; WALLERIAN DEGENERATION;

EID: 48249139449     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.30.051606.094313     Document Type: Review

References (162)

1. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, et al. 1994. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 36:76-82
2. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, et al. 2000. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:393-404
3. Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, et al. 1992. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am. J. Roentgenol. 159:1041-47
4. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. 1995. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 45:718-23
5. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. 2000. Neurological disability correlates withi spinal cord axonal loss and reduce N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48:893-901
6. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. 2001. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248-52
7. Bjartmar C, Yin X, Trapp BD. 1999. Axonal pathology in myelin disorders. J. Neurocytol. 28:383-95
8. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, et al. 1994. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:778-86
9. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. 2003a. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9:323-31
10. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. 2003b. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62:723-32
11. Bobholz JA, Rao SM. 2003. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr. Opin. Neurol. 16:283-88
12. Bostock H, Sears TA. 1978. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J. Physiol. 280:273-301
13. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, et al. 1999. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J. Neurosci. 19:7278-88
14. Brown GC, Borutaite V. 2002. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med. 33:1440-50
15. Brownell B, Hughes JT. 1962. Distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25:315-20
16. Calabrese M, Atzori M, Bernardi V, Morra A, Romualdi C, et al. 2 007. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J. Neurol. 254:1212-20
17. Chang A, Smith M, Yin X, Staugaitis SM, Trapp B. 2007. Neurogenesis in the chronic lesions of multiple sclerosis. J. Neuropathol. Exp. Neurol. 66:431
18. Charcot M. 1868. Histologie de la sclerose en plaques. Gaz Hosp. 141:554-5-57-8
19. Charil A, Dagher A, Lerch JP, Zijdenbos AP, Worsley KJ, Evans AC. 2007. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 34:509-17
20. Comi G, Filippi M, Wolinsky JS. 2001. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49:290-97
21. Compston A. 2006. Making progress on the natural history of multiple sclerosis. Brain 129:561-63
22. Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359:1221-31
23. Confavreux C, Vukusic S. 2006a. Age at disability milestones in multiple sclerosis. Brain 129:595-605
24. Confavreux C, Vukusic S. 2006b. Natural history of multiple sclerosis: a unifying concept. Brain 129:606-16
25. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, et al. 2000. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med. 192:393-404
26. Barkhof F, Scheltens P, Frequin ST, Nauta JJ, Tas MW, et al. 1992. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am. J. Roentgenol. 159:1041-47
27. Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. 1995. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 45:718-23
28. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. 2000. Neurological disability correlates with spinal cord axonal loss and reduce N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48:893-901
29. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. 2001. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57:1248-52
30. Bjartmar C, Yin X, Trapp BD. 1999. Axonal pathology in myelin disorders. J. Neurocytol. 28:383-95
31. Bo L, Dawson TM, Wesselingh S, Mork S, Choi S, et al. 1994. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36:778-86
32. Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. 2003a. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult. Scler. 9:323-31
33. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. 2003b. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J. Neuropathol. Exp. Neurol. 62:723-32
34. Bobholz JA, Rao SM. 2003. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr. Opin. Neurol. 16:283-88
35. Bostock H, Sears TA. 1978. The internodal axon membrane: electrical excitability and continuous conduction in segmental demyelination. J. Physiol. 280:273-301
36. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, et al. 1999. Formation of compact myelin is required for maturation of the axonal cytoskeleton. J. Neurosci. 19:7278-88
37. Brown GC, Borutaite V. 2002. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic. Biol. Med. 33:1440-50
38. Brownell B, Hughes JT. 1962. Distribution of plaques in the cerebrum in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 25:315-20
39. Calabrese M, Atzori M, Bernardi V, Morra A, Romualdi C, et al. 2007. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J. Neurol. 254:1212-20
40. Chang A, Smith M, Yin X, Staugaitis SM, Trapp B. 2007. Neurogenesis in the chronic lesions of multiple sclerosis. J. Neuropathol. Exp. Neurol. 66:431
41. Charcot M. 1868. Histologie de la sclerose en plaques. Gaz Hosp. 141:554-5-57-8
42. Charil A, Dagher A, Lerch JP, Zijdenbos AP, Worsley KJ, Evans AC. 2007. Focal cortical atrophy in multiple sclerosis: relation to lesion load and disability. Neuroimage 34:509-17
43. Comi G, Filippi M, Wolinsky JS. 2001. European/Canadian multicenter, double-blind, random ized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49:290-97
44. Compston A. 2006. Making progress on the natural history of multiple sclerosis. Brain 129:561-63
45. Compston A, Coles A. 2002. Multiple sclerosis. Lancet 359:1221-31
46. Confavreux C, Vukusic S. 2006a. Age at disability milestones in multiple sclerosis. Brain 129:595-605
47. Confavreux C, Vukusic S. 2006b. Natural history of multiple sclerosis: a unifying concept. Brain 129:606-16
48. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, et al. 1998. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469-77
49. de Waegh S, Brady ST. 1990. Altered slow axonal transport and regeneration in a myelin-deficient mutant mouse: the trembler as an in vivo model for Schwann cell-axon interactions. J. Neurosci. 10:1855-65
50. Dutta R, McDonough J, Yin X, Peterson J, Chang A, et al. 2006. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59:478-89
51. Ebers GC, Yee IM, Sadovnick AD, Duquette P. 2000. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann. Neurol. 48:927-31
52. ESGIB. 1998. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352:1491-97
53. Felts PA, Baker TA, Smith KJ. 1997. Conduction in segmentally demyelinated mammalian central axons. J. Neurosci. 17:7267-77
54. Ferguson B, Matyszak MK, Esiri MM, Perry VH. 1997. Axonal damage in acute multiple sclerosis lesions. Brain 120:393-99
55. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. 1998. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann. Neurol. 43:809-14
56. Fisher E, Chang A, Fox R, Tkach JA, Svarovsky T, et al. 2007. Imaging correlates of axonal swelling in chronic multiple sclerosis brains. Ann. Neurol. 62:219-28
57. Foong J, Rozewicz L, Davie CA, Thompson AJ, Miller DH, Ron MA. 1999. Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. J. Neuropsychiatry Clin. Neurosci. 11:45-50
58. Ganter P, Prince C, Esiri MM. 1999. Spinal cord axonal loss in multiple sclerosis: a postmortem study. Neuropathol. Appl. Neurobiol. 25:459-67
59. Greenfield JG, King LS. 1936. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain 59:445-58
60. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, et al. 2007. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39:1083-91
61. Griffin JW, Li CY, Ho TW, Xue P, Macko C, et al. 1995. Guillain-Barre syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain 118:577-95
62. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, et al. 1998. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610-13
63. Groom AJ, Smith T, Turski L. 2003. Multiple sclerosis and glutamate. Ann. N. Y. Acad. Sci. 993:229-75
64. Hafler DA, Compston A, Sawcer C, Lander E, Daly MJ, et al. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357:851-62
65. Haines JL, Terwedow HA, Burgess K, Pericak-Vance MA, Rimmler JB, et al. 1998. Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. The Multiple Sclerosis Genetics Group. Hum. Mol. Genet. 7:1229-34
66. Hauser S, Oksenberg JR. 2006. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 52:61-76
67. Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, et al. 1995. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and antiglycolipid antibodies. Brain 118:597-605
68. Hohlfeld R. 1997. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865-916
69. Horiguchi T, Kis B, Rajapakse N, Shimizu K, Busija DW. 2003. Opening of mitochondrial ATP-sensitive potassium channels is a trigger of 3-nitropropionic acid-induced tolerance to transient focal cerebral ischemia in rats. Stroke 34:1015-20
70. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. 2001. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J. Exp. Med. 194:669-76
71. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:285-94
72. Karadottir R, Cavelier P, Bergersen LH, Attwell D. 2005. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438:1162-66
73. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. 1999. Cortical lesions in multiple sclerosis. Brain 122:17-26
74. Kies M, Alvord EC, eds. 1959. Allergic Encephalomyelitis. Springfield, IL: Thomas
75. Kleinschmidt-DeMasters BK, Tyler KL. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369-74
76. Klugmann M, Schwab MH, Puhlhofer A, Schneider A, Zimmermann F, et al. 1997. Assembly of CNS myelin in the absence of proteolipid protein. Neuron 18:59-70
77. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. 2007. Selective modulation of the ery-thropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin. Biochim. Biophys. Acta 1776:1-9
78. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, et al. 1990. Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc. Natl. Acad. Sci. USA 87:1561-65
79. Kornek B, Lassmann H. 1999. Axonal pathology in multiple sclerosis. A historical note. Brain Pathol. 9:651-56
80. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, et al. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157:267-76
81. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. 2006. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 129:584-94
82. Kutzelnigg A, Lassmann H. 2005. Cortical lesions and brain atrophy in MS. J. Neurol. Sci. 233:55-59
83. Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, et al. 2003. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33:366-74
84. Lassmann H. 2003. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J. Neurol. Sci. 206:187-91
85. Lassmann H. 2004. Experimental autoimmune encephalomyelitis. In Myelin Biology and Disorders, ed. RA Lazzarini, pp. 1039-72. New York: Elsevier
86. Li C, Tropak MB, Gerial R, Clapoff S, Abramow-Newerly W, et al. 1994. Myelination in the absence of myelin-associated glycoprotein. Nature 369:747-50
87. (2+) exchange in spinal cord white matter injury at physiological temperature. J. Neurophysiol. 84:1116-19
88. Li S, Stys PK. 2000. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J. Neurosci. 20:1190-98
89. Li W, Maeda Y, Yuan RR, Elkabes S, Cook S, Dowling P. 2004. Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Ann. Neurol. 56:767-77
90. Lipton SA, Rosenberg PA. 1994. Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330:613-22
91. Liu JS, Zhao ML, Brosnan CF, Lee SC. 2001. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am. J. Pathol. 158:2057-66
92. Lovas G, Szilagyi N, Majtenyi K, Palkovits M, Komoly S. 2000. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123:308-17
93. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47:707-17
94. Lumsden CE. 1970. The neuropathology of multiple sclerosis. In Handbook of Clinical Neurology, ed. PJ Vinken, GW Bruyn, pp. 217-309. New York: Elsevier
95. Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, et al. 2007. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39:1108-13
96. Marburg O. 1906. Die sogenannte "akute multiple sklerose" (Encephalomyelitis peraxialis scleroticans). Jahrb Neurol. Psych. 27:211-312
97. Matthews PM, Pioro E, Narayanan S, De Stefano N, Fu L, et al. 1996. Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119:715-22
98. Matute C, Alberdi E, Domercq M, Perez-Cerda F, Perez-Samartin A, Sanchez-Gomez MV. 2001. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 24:224-30
99. Matute C, Domercq M, Sanchez-Gomez MV. 2006. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 53:212-24
100. McDonald LJ, Moss J. 1993. Stimulation by nitric oxide of an NAD linkage to glyceraldehyde-3-phosphate dehydrogenase. Proc. Natl. Acad. Sci. USA 90:6238-41
101. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:121-27
102. McKhann GM, Cornblath DR, Ho TW, Li CY, Bai AY, et al. 1991. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet 338:593-97
103. Medana I, Martinic MA, Wekerle H, Neumann H. 2001. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol. 159:809-15
104. Micu I, Jiang Q, Coderre E, Ridsdale A, Zhang L, et al. 2006. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 439:988-92
105. Mignot E. 1998. Genetic and familial aspects of narcolepsy. Neurology 50:S16-22
106. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. 2002. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676-95
107. Miller DH, Barkhof F, Nauta JJ. 1993. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116:1077-94
108. Morgen K, Sammer G, Courtney SM, Wolters T, Melchior H, et al. 2007. Distinct mechanisms of altered brain activation in patients with multiple sclerosis. Neuroimage 37:937-46
109. +-ATPase inhibition by nitric oxide and peroxynitrite anion. J. Appl. Toxicol. 23:275-78
110. Nave K-A, Trapp BD. 2007. Molecular biology of myelination. Annu. Rev. Neurosci. 31:535-61
111. Neuhaus O, Farina C, Wekerle H, Hohlfeld R. 2001. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702-8
112. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. 2000. Multiple sclerosis. N. Engl. J. Med. 343:938-52
113. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, et al. 2004. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62:2038-43
114. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, et al. 2004. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am. J. Hum. Genet. 74:160-67
115. Pantano P, Iannetti GD, Caramia F, Mainero C, Di Legge S, et al. 2002. Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain 125:1607-15
116. Parpura V, Scemes E, Spray DC. 2004. Mechanisms of glutamate release from astrocytes: gap junction "hemichannels", purinergic receptors and exocytotic release. Neurochem. Int. 45:259-64
117. Parry AM, Scott RB, Palace J, Smith S, Matthews PM. 2003. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 126:2750-60
118. Paty DW, Li DK. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662-67
119. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. 2001. Transected neurites, apoptotic neurons and reduced inflammation in cortical MS lesions. Ann. Neurol. 50:389-400
120. Peterson JW, Kidd GJ, Trapp BD. 2005. Axonal degeneration in multiple sclerosis: the histopathological evidence. In Multiple Sclerosis as a Neuronal Disease, ed. S Waxman, pp. 165-84. New York: Elsevier
121. Pirko I, Lucchinetti CF, Sriram S, Bakshi R. 2007. Gray matter involvement in multiple sclerosis. Neurology 68:634-42
122. Pitt D, Werner P, Raine CS. 2000. Glutamate excitotoxicity in a model of multiple sclerosis. Nat. Med. 6:67-70
123. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899-910
124. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. 2005. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann. Neurol. 58:840-46
125. PRISMS. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-504
126. Putnam TJ. 1936. Studies in multiple sclerosis. Arch. Neurol. Psych. 35:1289-308
127. Rao SM, Leo GJ, Bernardin L, Unverzagt F. 1991. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685-91
128. Reddy H, Narayanan S, Arnoutelis R, Jenkinson M, Antel J, et al. 2000. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 123:2314-20
129. + channels in C-type DRG neurons by S-nitrosylation. J. Neurophysiol. 87:761-75
130. Rivers TM, Sprunt DH, Berry GP. 1933. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 58:39-53
131. Rocca MA, Mezzapesa DM, Falini A, Ghezzi A, Martinelli V, et al. 2003. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically iso-lated syndromes suggestive of multiple sclerosis. Neuroimage 18:847-55
132. Ron MA, Callanan MM, Warrington EK. 1991. Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. Psychol. Med. 21:59-68
133. Rosati G. 2001. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22:117-39
134. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. 1999a. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698-704
135. Rudick RA, Goodman A, Herndon RM, Panitch HS. 1999b. Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment. J. Neuroimmunol. 98:22-28
136. Salter MG, Fern R. 2005. NMD A receptors are expressed in developing oligodendrocyte processes and mediate injury. Nature 438:1167-71
137. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA. 1996. Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J. Neurosci. 16:5095-105
138. Sharma R, Narayana PA, Wolinsky JS. 2001. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult. Scler. 7:221-26
139. Sheikh KA, Ho TW, Nachamkin I, Li CY, Cornblath DR, et al. 1998. Molecular mimicry in Guillain-Barre syndrome. Ann. N. Y. Acad. Sci. 845:307-21
140. Shields DC, Schaecher KE, Saido TC, Banik NL. 1999. A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc. Natl. Acad. Sci. USA 96:11486-91
141. Shiraki H, Otani S. 1959. Clinical and pathological features of rabies postvaccinal encephalomyelilitis in man. See Kies & Alvord 1959, pp. 58-129
142. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, et al. 1998. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. 43:79-87
143. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, et al. 1999. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139-48
144. Smith KJ, Lassmann H. 2002. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1:232-41
145. Smith T, Groom A, Zhu B, Turski L. 2000. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat. Med. 6:62-66
146. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. 2005. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 128:1016-25
147. Steinman L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:762-64
148. 2+ exchanger. J. Neurosci. 12:430-39
149. Tafti M, Dauvilliers Y. 2003. Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics 4:23-33
150. Tekkök SB, Goldberg MP. 2001. AMPA/kainate receptor activation mediates hypoxic oligodendrocyte death and axonal injury in cerebral white matter. J. Neurosci. 21:4237-48
151. Trapp BD, Kidd GJ. 2004. Structure of the myelinated axon. In Myelin Biology and Disorders, ed. R Lazzarini, pp. 3-25. New York: Elsevier
152. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. 1998. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338:278-85
153. Trapp BD, Ransohoff RM, Fisher E, Rudick RA. 1999. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5:48-57
154. Uchimura I, Shiraki J. 1957. A contribution to the classification and the pathogenesis of demyelinating encephalomyelitis; with special reference to the central nervous system lesions caused by preventive inoculation against rabies. J. Neuropathol. Exp. Neurol. 16:139-203
155. Waksman BH. 1959. Evidence favoring delayed sensitization as the mechansims underlying experimental "allergic" encephalomyelitis. See Kies & Alvord 1959, pp. 419-43
156. Weinshenker BG. 1996. Epidemiology of multiple sclerosis. Neurol. Clin. 14:291-308
157. Wolinsky JS, Narayana PA, Johnson KP. 2001. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult. Scler. 7:33-41
158. Ye ZC, Wyeth MS, Baltan-Tekkok S, Ransom BR. 2003. Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J. Neurosci. 23:3588-96
159. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. 1992. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356:63-66
160. Yn X, Baek RC, Kirschner DA, Peterson A, Fujii Y, et al. 2006. Evolution of a neuroprotective function of central nervous system myelin. J. Cell Biol. 172:469-78
161. Yin X, Crawford TO, Griffin JW, Tu P-H, Lee VMY, et al. 1998. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 18:1953-62
162. + ATPase in chronic MS lesions. Ann. Neurol. In press